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Abstract: There are both histomorphometric
and
nonhistomorphometric
studies
confirming that etidronate reduces bone
resorption. In this study, we have examined
urinary Calcium/Creatinine ratio (uCA/Cr) as
a biochemical marker of bone turnover to
show the effectiveness of etidronate and
whether it could be used as a follow–up
parameter of treatment. Eighty–one
postmenopausal women aged 40 to 65
included into the study to investigate the
effects of etidronate on uCa/Cr in a
prospective, randomised, placebo controlled
clinical trial. All necessary criteria matched 81
women were divided into 3 groups at
random, each group consisted of 27 patients.
Prior to treatment, uCa/Cr was calculated
from all subjects 3 hours after drinking 1
liter of water in the morning. Twenty seven
(33.3%) women were randomised to oral
doses of etidronate (400 mg/day for two
weeks followed by drug free period of 10
weeks), twenty seven women to etidronate
(400 mg/day for two weeks) plus calcium
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Introduction
The loss of ovarian hormones in menopause is a major
risk factor for osteoporosis (1–2). It has been estimated
that the risk of a woman developing fractures later in life
is as great as that of cardiovascular disease and six times
higher than that for breast cancer (3). Prevention of bone
loss with hormone replacement therapy (HRT) has been
shown to reduce the incedence of vertebral and hip
fractures (4–5). However, HRT is associated with risks,
some of which are well documented, whereas others
(such as an apparent increased incidence of breast cancer)
remain unproven. Side effects, such as withdrawal
bleeding, together with concerns for long–term safety,
limit the acceptability of long–term estrogen treatment
(6). It has, therefore, been of great interest to find new

(1000 mg/day) for the following 10 weeks
and twenty seven women to placebo (Fe, 50
mg/day) for 12 weeks. After 12 weeks of
treatment, uCa/Cr declined significantly in the
etidronate group from 0.118±0.064 to
0.053±0.021, in etidronate+calcium group
from 0.08±0.03 to 0.06±0.015 ((p=0.004)
and (p=0.005), respectively). In the placebo
group no significant change was observed
(p=0.03). In conclusion, etidronate is
effective in postmenopausal women and the
effectiveness of treatment may be followed
up by measuring uCa/Cr which is a simple and
cheap parameter of determining the
effectivensess of etidronate in prevention of
osteoporosis. However, since there are
contradictory findings concerning uCa/Cr
exist, larger clinical and prospective studies
should be carried out.
Key
Words:
Etidronate,
Calcium/Creatinin
ratio,
replacement therapy.
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therapies that can prevent the postmenopausal bone loss
in younger and elderly women and eventually decrease
the incedence of fractures. Since 1970’s, biphosphonates
have been in use for prevention of osteoporosis,
especially in the treatment of tumor–induced
hypercalcemia (7) and for the treatment of bone
metastases as the essential pathogenic role of osteoclasts
in tumor–induced osteolysis is now well established (8).
Biphosphonates, analogues of inorganic pyrophosphate, a
naturally inhibitor of bone mineralization, strongly bind
to the bone mineral, hydroxyapatite, thus inhibiting
resorption (9) and potentially affecting mineralization as
well (10). A variety of treatment regimens employed
continuous (11) or intermittent (12, 13) oral
biphosphonate administration. These antiresoptive agents
include drugs such as etidronate, pamidronate,
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alendronate, coldronate, which have been shown to
inhibit osteoclastogenesis and to cause apoptosis of active
osteoclasts (14). The first biphosphonate to be
investigated in large clinical studies was etidronate and its
eficacy and safety of cyclical etidronate in the treatment
of established osteoporosis is well established (12). Since
continuous oral treatment with high doses of etidronate
may lead to impairment of bone mineralization and the
cessation of bone remodeling, a more ideal therapeutic
regimen might consist of the intermittent cyclic
administration of etidronate at a dose that inhibits bone
resorption yet does not prevent mineralization (12).
Biochemical parameters of bone resorption can be used
for a sensitive and specific assessment of the osteolysis
and also the effect of the drug administered to treat
osteoparasis (15). The markers of bone resorption are
pyridinoline, CroosLaps, hydroxyproline and urinary
calcium (uCa), whereas, alkaline phosphatase (ALP) and
osteocalcin are the markers of bone formation. Among
those nonhistomorphometric parameters, urinary
excretion of calcium is the classical and widely available
parameter (15). In this sudy, we have investigated the
efficacy of etidronate on osteoporosis by measuring
uCa/Cr which is a simple and cheap parameter. In
addition, we searched its usefulness for assessment of
effectiveness of etidronate on osteoporosis.

Blood and urine samples were obtained after 12 h fast
from all patients. Serum chemistry included calcium (Ca),
creatinin (Cr) and ALP and urinary Ca and Cr were
assayed by Olympus AU 600 autoanalyser. Serum FSH,
LH, estradiol were measured by chemiluminescence
(Immulite; DPC). Urine samples were collected 3 hours
later, after drinking 1 liter of water in the morning, to
assay uCa/Cr (16). Following the biochemical work–up,
all subjects were treated as they were randomly allocated
to. Twenty seven (33.3%) women were randomised to
oral doses of etidronate (400 mg/day for two weeks
followed by drug free period of 10 weeks), twenty seven
women to editronate (400 mg/day for two weeks) plus
calcium (1000 mg/day) for the following 10 weeks and
twenty seven women to placebo (Fe, 50 mg/day) for 12
weeks and followed up prospectively.
At the end of three months of treatment, using the
same tecniques, serum Ca, ALP, Cr levels and uCA/Cr
were measured. FSH, LH, E2 levels and pretreatment and
posttreatment demographic values of serum Ca, ALP, Cr
and uCa/Cr were analysed. Paired–t test, one way
analyses of variance (ANOVA) and Neuman–Keuls
comparison tests were used for statistical analyses.
p<0.05 value was accepted as statistically significant.
Results

Material and Method
Eighty–one women with natural or surgical
menopause aged 40 to 65 were studied. Patients who
had hysterectomy and bilateral oophorectomy included
provided that FSH was in the postmenopausal range.
Exclusion criteria were: any disease known to affect bone
metabolism; treatment with calcitonin, vitamin D (at
doses > 400 U/day), elemental calcium (at doses > 500
mg/day), carticosceroids, or anabolic steroids within the
past 6 months; treatment with estrogens and/or
progestagens within the past year. Patients were
weighing between 49 and 87kg and within 20% of their
normal body mass index (BMI<29 kg/m2).

Results were given as mean values ±SD. The mean
demographic data are shown in Table 1 and all groups
were comparable with respect to all demographic data
(p=0.496, p=299, p=0.32 and p=0.34 respectively)
(Table 1). Also no significant difference between three
groups in terms of E2, FSH and LH levels was seen
(p=0.689, p=0.79 and p=0.4 respectively) (Table 2).
Serum Ca and ALP levels prior to and after treatment
have not shown any significant difference among the
groups (p=0.4) (Table 3).
While uCA/Cr decreased significantly in etidronate
group from 0.118±0.064 to 0.053±0.028 (p=0.004)
and from 0.08±0.0 to 0.06±0.015 (p=0.005) in

Table 1.
E
Age
Gravida
Parity
Duration of menopause
* p > 0.05, ANOVA
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52.8±6.9
4.6±1.5
4.2±1.4
6.1±0.5

(NS): Not significant.

Pl
50.6±4.1
4.9±1.5
4.4±1.1
5.9±0.4

E+Ca

P

52±4.8
4.7±1.8
4.3±0.7
6.05±0.4

0.496
0.299
0.32
0.34

(NS)
(NS)
(NS)
(NS)

Age, parity, pregnancy rate
and duration of menopause
of patients (E: Etidronate,
Pl:
Placebo,
E+Ca:
Etidronate+Calcium).
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E
E2 (pg/ml)
FSH (mIU/ml)
LH (mIU/ml)
* p > 0.05, ANOVA

Serum Ca
(mg/dl)
Serum ALP
(U/L)

P:
A:
P:
A:

* p > 0.05, ANOVA

Pl

31.6±5.5
66.7±7.3
82.8±10.1

E+Ca

35.3±6.6
68.6±5.6
79.5±6.7

Table 2.

E2, FSH, LH levels of
groups.

Table 3.

Serum Ca++ ad creatinin
levels of groups prior to (P)
and after (A) treatment.

P

34.9±6.2
70.3±6.8
78.4±8.4

0.689 (NS)
0.79 (NS)
0.4
(NS)

(NS): Not significant.

E

Pl

E+Ca

P

9.9±0.7*
10.1±0.8^
95±23.3*
97±21.4^

9.69±0.6*
9.7±0.7^
90±16.7*
93±18.3^

9.78±0.6*
9.9±0.7^
98.6±27.6*
96±25.3^

0.4
0.4

^ p> 0.05, Paired–t test.

etidronate+Calcium group, the drop in placebo group
from 0.093±0.045 to 0.088±0.036 (p=0.3) was not
significant following 3 months of treatment (Table 4).
During treatment no severe side effects were
observed and no reason intervening with treatment has
occurred in all groups. One patient, in each etidronate
group, complained of nausea and diarrhea, and in the
placebo group, two patients had nausea probably due to
irritating effect of Fe on gastric mucosa.
Discussion
A large number of studies have shown the
effectiveness of HRT in prevention of osteoporosis during
menopause (4, 5) but its use is not without limitation due
to associated risks (6). This knowledge led to alternative
treatment modalities of osteoporosis in patients in whom
HRT is contraindicated. In this point, biphosphonates
have been used for osteoporosis since 1970’s. The
efficacy and safety of cyclical etidronate in reducing bone
resorption through the inhibition of osteoclastic activity in

osteoporosis is well established (12, 17, 18, 19, 20).
However it seems that drug interferes with
mineralisation of newly formed bone when given
continuously, but this can be prevented by cyclical
administration (12).
There
are
both
histomorphometric
and
nonhistomorphometric studies confirming that etidronate
reduces bone resorption. Although, in most of the
refferences, dual energy x–ray absorpsiometry (DEXA)
has been used in addition to nonhistomorphometric
parameters for bone mineral density measurements, this
histomorphometric tecnique costs relatively high. We do
not argue that uCa/Cr is an alternative parameter to
DEXA. Since uCa/Cr is a widely available measurement
and very cheap, we decided to use uCa/Cr as a
biochemical marker of bone turnover to show the
effectiveness of etidronate and whether it could be used
as a follow–up parameter of treatment. We found that
etidronate is effective in postmenopausal women by
decreasing bone resorption. We found that etidronate is
effective in postmenopausal women by decreasing bone

Table 4.
Group
E
Pl
E+Ca++

(n:27)^
(n:27)
(n:27)^

P

A

p

0.118±0.064
0.093±0.045
0.08±0.030

0.053±0.028
0.088±0.036
0.06±0.015

0.004
0.3
0.005

Urinary Calcium/Creatinin
ratio of groups prior to (P)
and after (A) treatment.

(S)
(NS)
(S)

^p < 0.05, Paired–t test (S): Significant (NS): Not significant.
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resorption. In addition, the effectiveness of treatment
may be followed up by simply measuring uCa/Cr. Smith et
al. (21) have observed pre and post operative
nonhistomorophometric parameters of bone turnover in
intervals of 3 months in 20 healthy premenopausal and
found that following 3 months of daily 400 mg
editronate administration, the levels returned to
premenopausal state. Reitsman et al. (22), by daily
Pamidronate (biphosphanates) injections to rats, showed
that suppression of both velocity and degree of bone
resorption depends on dose regimen by measuring
urinary hydroxyproline excretion. In our study, similar to
the results by Smith et al. (21) in etidronate given groups
uCa/Cr declined appreciably more than that in placebo
group. That we have not documented any significant
change in serum Ca levels (p=0.4) differs from the results
by Smith et al. (21). Also the reported progressive
increase in ALP levels in placebo group by these authors
was not significant in our study (p=0.4).uCa/Cr in the
placebo group was similar and no change in the ratio was
observed after treatment (p=0.3).

Decline in uCa/Cr in this study was comparable to the
results reported by some studies (23, 24, 25, 26, 27,
28). Contradiction to this finding is that some reports
have shown no difference in uCa/Cr in patients treated
with biphophonates (17, 18, 29, 30). This could be
simply due to the drug used and/or the characteristics of
population studied.
In this study, we concluded that etidronate is effective
in postmenopausal women and the effectiveness of
treatment may be followed up by measuring uCa/Cr
which is a simple and cheap method of determining the
effectiveness of treatment in prevention of osteoporosis.
However, since there are contradictory findings
concerning uCa/Cr exist, larger clinical and prospective
studies should be carried out.
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